

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES BEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/616,055	07/09/2003	Amarpreet S. Sawhney	3516.10US02	9525
62274 DADDI & ASS	7590 02/12/200° SOCIATES, PLLC	EXAMINER		
220 S. 6TH ST	•		WEBMAN, EDWARD J	
SUITE 2000, U.S. BANK PLAZA MINNEAPOLIS, MN 55402			ART UNIT	PAPER NUMBER
			1616	
				<u> </u>
SHORTENED STATUTOR	RY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
2 MONTHS		02/12/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)				
		10/616,055	SAWHNEY, AMARPREET S.				
	Office Action Summary	Examiner	Art Unit				
		Edward J. Webman	1616				
	The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period fo	• •						
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timused and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status			·				
1)⊠	Responsive to communication(s) filed on 17 No	ovember 2006.					
• —	This action is FINAL . 2b) ☐ This action is non-final.						
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
4)⊠	4)⊠ Claim(s) <u>1-69</u> is/are pending in the application.						
• -	4a) Of the above claim(s) 9,10,32,33 and 58 is/are withdrawn from consideration.						
5)□	5) Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>1-8,11-31,34-57 and 59-69</u> is/are rejected.						
7)	Claim(s) is/are objected to.						
8)□	Claim(s) are subject to restriction and/o	r election requirement.					
Applicati	on Papers						
9) The specification is objected to by the Examiner.							
10)	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	ınder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
 Certified copies of the priority documents have been received. 							
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachmen	t(s)						
	e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
	e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal P					
	r No(s)/Mail Date	6) Other:					

Application/Control Number: 10/616,055

Art Unit: 1616

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-8, 11-31, 34-57, 59-69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hubbell et al (US 5,843,743) in view of Cole et al (US 4,948,575)

Hubbell et al '743 teach gels comprising polymerized macromers used as supports for contact of biological materials with the body (title, abstract). PEG diacrylate is specified (column 5 line 66). Albumin is disclosed (column 6 line 49). Crosslinking is taught (column 5 line 12). Inorganic drugs are specified (column 8 line 21). Active peptides are disclosed (column 8 line 20). Cylinders and spheres are specified (column 13 line 56); microspheres are disclosed (column 9 line 61).

Cole et al teach the addition of an acid and carbonate salt as two separate components to generate carbon dioxide and thereby form a gel foam (title, abstract, Column 3 lines 49-56, column 3 line 68-column 4 line 4, column 4 lines 32-40).

Prolonging the healing process of a wound is disclosed (column 2 lines 58-62).

Application/Control Number: 10/616,055

Art Unit: 1616

It would have been obvious to one of ordinary skill to add an acid and carbonate salt as to separate components to the composition Hubbell et al '743 to achieve the beneficial effect of a foaming gel which prolongs the healing process of a wound.

As to the claimed properties of hydration and shape to occlude a space upon hydration, such must be inherently possessed by the obvious composition because it is the same as that claimed. (See MPEP 2112 for inherency arguments in 103 rejections.) As to the claimed radio-opaque agent and dispersion of a hydrophobic agent, the addition of barium sulfate as a diagnostic agent would be an obvious expedient.

Applicant's argument that there is no motivation to combine because most artisans wish to accelerate wound healing is not germaine to the particular primary reference herein which is silent on wound healing. Applicant also argues that Cole et al teaches away from the primary reference in that it teaches away from a lack of dimensional stability. However, Cole et al's use of "may" indicates that the teaching is merely advisory.

No claims allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 10/616,055

Art Unit: 1616

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Edward J. Webman whose telephone number is 571-272-0633. The examiner can normally be reached on M-F from 8 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, J. Richter, can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).